References of "Vranken, Laura"
     in
Bookmark and Share    
Peer Reviewed
See detailActive vitamin B12: detection and clinical implications
VRANKEN, Laura ULg

Conference (2012, October 25)

Detailed reference viewed: 10 (0 ULg)
Full Text
See detailThe thyrogastric syndrome : an under diagnosed etiology for acquired gastric neuroendocrine tumors. A case report
VALDES SOCIN, Hernan Gonzalo ULg; LOLY, Jean ULg; GAST, Pierrette ULg et al

in Abstract Book - 13th International Workshop on Multiple Endocrine Neoplasia (2012, September)

Detailed reference viewed: 43 (10 ULg)
Full Text
Peer Reviewed
See detailInterpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values
CAVALIER, Etienne ULg; DELANAYE, Pierre ULg; VRANKEN, Laura ULg et al

in Nephrology Dialysis Transplantation (2012), 27

Background. The recommended target range for serum parathyroid hormone (PTH) in dialysis patients has changed from 150 to 300 pg/mL in the KDOQI guidelines to two to nine times the upper normal limit in ... [more ▼]

Background. The recommended target range for serum parathyroid hormone (PTH) in dialysis patients has changed from 150 to 300 pg/mL in the KDOQI guidelines to two to nine times the upper normal limit in the KDIGO ones. Although inclusion/exclusion criteria for the reference population are highly important, they are usually not mentioned in the commercial kits. In this study, we used the same reference population of vitamin D-replete normal subjects to establish reference values for 10 commercial PTH kits. We evaluated whether this may improve the classification of dialysis patients according to the KDIGO compared to the use of reference values proposed by the manufacturers. Methods. We measured serum PTH with 10 different kits in 149 haemodialysis patients, and 240 25-OH-vitamin D-replete (>75 nmol/L) individuals with an estimated glomerular filtration rate >60 mL/min/1.73 m2. Results. For the 10 kits, our upper normal limit was lower than those of the manufacturers. The difference was, however, variable from one kit to another. The two kits that yielded the lowest and the highest absolute concentrations classified differently 84/149 patients (56.4%) according to the KDOQI and 53/149 (36.2%) according to the KDIGO using the manufacturers’ normal value.Using our normal values significantly decreased the discrepancies with 24/149 patients (16.1%) being still classified differently. Taking the measurement uncertainty into consideration, 8% of the patients only remained differently classified by these two kits. Conclusions. Using the same vitamin-D-replete population to establish the reference range for 10 commercial PTH kits significantly improved the classification of haemodialysis patients according to the KDIGO target range. [less ▲]

Detailed reference viewed: 67 (9 ULg)
Full Text
See detailDrospirenone and interference with renin-antiotensin system
VROONEN, Laurent ULg; Cavalier, Etienne ULg; Vranken, Laura ULg et al

in Annales d'Endocrinologie - 28ème congrès de la société Française d'Endocrinologie (2011)

Detailed reference viewed: 64 (5 ULg)
Full Text
See detailInfluence of drospirenone on renin-angiotensin-aldosterone system evaluation
VROONEN, Laurent ULg; Cavalier, Etienne ULg; Vranken, Laura ULg et al

in Endocrine Abstracts - 13th European Congress of Endocrinology (2011)

Detailed reference viewed: 32 (4 ULg)